Drug Profile

DLX 7

Alternative Names: DLX-007; DLX-7; TBG

Latest Information Update: 06 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Delix Therapeutics
Class Antidepressants; Azepines; Indoles; Neuropsychotherapeutics; Small molecules
Mechanism of Action Serotonin 5-HT2A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Substance-related disorders
No development reported CNS disorders

Most Recent Events

06 Feb 2026 Preclinical trials in Substance-related disorders in USA (PO), prior to February 2026 (Delix Therapeutics pipeline, February 2026)
28 May 2025 No recent reports of development identified for preclinical development in CNS-disorders in USA (PO)
14 Feb 2023 Delix Therapeutics plans a phase I clinical trial for CNS disorders, in the first half of 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com